CoChat

Lactiplantibacillus plantarum strains KABP011, KABP012, and KABP013 modulate bile acids and cholesterol metabolism in humans

Open access
Padro, Teresa, Santisteban, Victoria, Huedo, Pol, Puntes, Montserrat, Aguiló, Meritxell, Espadaler-Mazo, Jordi, Badimon, Lina · 2024 · Cardiovascular Research

The DOI matches its Crossref record; 69 of the 71 references it cites were found in a registry or an index; 15 of the 25 sources its claims cite were checked for support.

Abstract

AIMS: Probiotics with high bile salt hydrolase (BSH) activity have shown to promote cardiovascular health. However, their mechanism(s) of action remain poorly understood. Here, we performed a pilot exploratory study to investigate effects of a 4-week intervention with escalating doses of a BSH-active formula containing Lactiplantibacillus plantarum strains KABP011, KABP012, and KABP013 on bile acid (BA), lipid profile, and lipoprotein function. METHODS AND RESULTS: Healthy overweight individuals were included in this study. The probiotic intake was associated with a progressive decrease of conjugated BAs in serum, due to the reduction of tauro- and glyco-conjugated forms. Plasma levels of fibroblast growth factor-19 were significantly reduced and correlated with BA changes. The probiotic induced significant changes in serum lipids, with reduction in non-HDL cholesterol (non-HDLc) and LDL cholesterol (LDLc) levels. The largest decrease was evidenced in the subgroup with higher baseline LDLc levels (LDLc > 130 mg/dL). Fasting levels of circulating apolipoprotein(Apo) B100 and ApoB48 were significantly reduced. Importantly, the decrease in non-HDLc levels was associated with a significant reduction in small LDL particles. Functional testing indicated that LDL particles had a significantly lower susceptibility to oxidation, while HDL particles gained antioxidant capacity after the probiotic intake. The microbiota profile in faeces collected at the end of the study was enriched with members of class Desulfovibrio, a taurine-consuming bacteria, likely because of the increase in free taurine in the gut due to the BSH activity of the probiotic. CONCLUSION: The intervention with L. plantarum strains induces beneficial effects on BA signature and lipoprotein profile. It reduces ApoB and small LDL levels and LDL susceptibility to oxidation and increases HDL antioxidant capacity. These metabolic profile changes suggest increased protection against atherosclerotic disease.

Overview

CoChat Summary

## TL;DR

In this 4-week single-arm pilot study of 20 healthy overweight adults, escalating doses of a BSH-active L. plantarum formula were associated with reduced conjugated bile acids, lower non-HDLc/LDLc, and improved lipoprotein function. The authors interpret these changes as a pattern potentially protective against atherosclerosis, but the design was exploratory and uncontrolled.

## Key findings

  • Serum conjugated bile acids fell progressively during the intervention: by Day 14 they were 1.4-fold lower than baseline (P = 0.007) and by Day 28 they were 1.7-fold lower (P = 0.006); non-conjugated bile acids did not change.
  • Plasma FGF-19 decreased significantly by the end of the intervention versus baseline (P = 0.011), and FGF-19 changes correlated with bile acid changes.
  • Lipids improved: non-HDLc decreased significantly after 1 week by −6.2 mg/dL (P = 0.033), LDL particles became less susceptible to oxidation (P < 0.001), and HDL gained antioxidant capacity.
  • ApoB100 and ApoB48 were significantly reduced after the first week and stayed reduced; small LDL particles also decreased, with the largest lipid reductions in the subgroup with baseline LDLc > 130 mg/dL.

## Methods

  • Single-centre, single-arm, dose-escalation longitudinal intervention with a 2-week run-in and 4-week probiotic period; all participants received escalating weekly doses of AB-LIFE® containing L. plantarum KABP011, KABP012, and KABP013.
  • Sample: 20 healthy overweight volunteers aged 25–60 years (10 men, 10 women); excluded were people with chronic disease, prior CVD, or lipid-lowering/other specified medications.
  • Main analyses used serial blood and stool measures at baseline and Days 7, 14, 21, and 28, including bile acids by UHPLC-MS, lipoproteins by NMR, lipoprotein functionality assays, immunoassays, and microbiota profiling by 16S rRNA sequencing.

## Limitations

  • The paper explicitly states the study’s limitations were the single-arm design and small sample size; it also notes that a placebo effect cannot be excluded.
  • The authors also state that the stool sampling was only a spot sample, which did not allow measurement of total fecal bile acid excretion.
  • Evident from the text: the study population was limited to 20 healthy overweight adults without major comorbidity, so generalizability to hypercholesterolaemic or diseased populations is uncertain.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/cvr/cvae061

Cites

69 of 70 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Graphical Abstract
Graphical Abstract CC BY · PubMed Central
Figure 1 Effect of the 4-week probiotic intervention on serum BA levels. (A) Cell line chart of median, Quartile 1, and Quartile 3 of total BAs measured by colorimetric enzymatic assays. (B) Box plot of conjugated BAs measured by UHPLC-MS. (C) Individual average change of total conjugated BA and primary and secondary conjugated BA. (D) Box plot of the ratio of non-conjugated/conjugated BA and (E) the ratio of total primary/total secondary BA. P-value: (A) Wilcoxon signed-rank test. (B) Friedman non-parametric test for repeated measures. (C) Student’s t-test for one sample. (D and E) Wilcoxon signed-rank test and Friedman non-parametric test for repeated measures. Statistical significance: P < 0.05. N = 20 for all time points in each panel. D, day; RI, relative intensity; Vol. Serum, volume of serum; Δ, change.
Figure 1 Effect of the 4-week probiotic intervention on serum BA levels. (A) Cell line chart of median, Quartile 1, and Quartile 3 of total BAs measured by colorimetric enzymatic assays. (B) Box plot of conjugated BAs measured by UHPLC-MS. (C) Individual average change of total conjugated BA and primary and secondary conjugated BA. (D) Box plot of the ratio of non-conjugated/conjugated BA and (E) the ratio of total primary/total secondary BA. P-value: (A) Wilcoxon signed-rank test. (B) Friedman non-parametric test for repeated measures. (C) Student’s t-test for one sample. (D and E) Wilcoxon signed-rank test and Friedman non-parametric test for repeated measures. Statistical significance: P < 0.05. N = 20 for all time points in each panel. D, day; RI, relative intensity; Vol. Serum, volume of serum; Δ, change.CC BY · PubMed Central
Figure 2 Effect of the 4-week probiotic intervention on FGF-19 levels in plasma. (A) Box plot of FGF-19 levels during intervention period. (B) Cell line chart of FGF-19 levels of each individual. (C) Table of spearman correlation of FGF-19 average change with average change of total primary, total secondary, non-conjugated, and conjugated BA. P-value: (A) Friedman non-parametric test for repeated measures, (A and B) Wilcoxon signed-rank test, and (C) Spearman’s rank correlation coefficient tests. Statistical significance: P < 0.05. N = 20 for all time points in each panel. FGF, fibroblast growth factor; BA, bile acids; D, day.
Figure 2 Effect of the 4-week probiotic intervention on FGF-19 levels in plasma. (A) Box plot of FGF-19 levels during intervention period. (B) Cell line chart of FGF-19 levels of each individual. (C) Table of spearman correlation of FGF-19 average change with average change of total primary, total secondary, non-conjugated, and conjugated BA. P-value: (A) Friedman non-parametric test for repeated measures, (A and B) Wilcoxon signed-rank test, and (C) Spearman’s rank correlation coefficient tests. Statistical significance: P < 0.05. N = 20 for all time points in each panel. FGF, fibroblast growth factor; BA, bile acids; D, day.CC BY · PubMed Central
Figure 3 Effect of the 4-week probiotic intervention on lipid levels. Cell line chart representing the median change with respect to baseline of serum non-HDLc, LDLc, and remnant cholesterol during probiotic intervention period. Table P-values correspond to Wilcoxon signed-rank test between change at one point with respect to baseline vs. change at prior point with respect to baseline, i.e. (D14–D0) levels vs. (D7–D0) levels. Statistical significance: P < 0.05. N = 20 for all time points. Δ, change; D, day; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol.
Figure 3 Effect of the 4-week probiotic intervention on lipid levels. Cell line chart representing the median change with respect to baseline of serum non-HDLc, LDLc, and remnant cholesterol during probiotic intervention period. Table P-values correspond to Wilcoxon signed-rank test between change at one point with respect to baseline vs. change at prior point with respect to baseline, i.e. (D14–D0) levels vs. (D7–D0) levels. Statistical significance: P < 0.05. N = 20 for all time points. Δ, change; D, day; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol.CC BY · PubMed Central
Figure 4 Effect of 4-week intervention with probiotic on ApoB levels. Box plots representing (A) ApoB48 and (B) ApoB100 levels. Individual average change of (C) ApoB48 and (D) ApoB100 during probiotic intervention. P-value: Wilcoxon signed-rank test. Statistical significance: P < 0.05. N = 20 for all time points in each panel. Apo, apolipoprotein; D, day.
Figure 4 Effect of 4-week intervention with probiotic on ApoB levels. Box plots representing (A) ApoB48 and (B) ApoB100 levels. Individual average change of (C) ApoB48 and (D) ApoB100 during probiotic intervention. P-value: Wilcoxon signed-rank test. Statistical significance: P < 0.05. N = 20 for all time points in each panel. Apo, apolipoprotein; D, day.CC BY · PubMed Central
Figure 5 Effect of 4-week intervention with probiotic on LDL lipoproteins. Box plots representing (A) LDL diameter and (B) small LDL particles concentration at baseline and Days 14 and 28. (C and D) Individual difference of number of small LDL particles at (B) Day 14 and at (C) Day 28 with respect to Day 0. P-value: (A and B) Friedman non-parametric test for repeated measures. (C and D) Student’s t-test for one sample. Statistical significance: P < 0.05. N = 20 for all time points in each panel. LDL, low-density lipoproteins; D, day.
Figure 5 Effect of 4-week intervention with probiotic on LDL lipoproteins. Box plots representing (A) LDL diameter and (B) small LDL particles concentration at baseline and Days 14 and 28. (C and D) Individual difference of number of small LDL particles at (B) Day 14 and at (C) Day 28 with respect to Day 0. P-value: (A and B) Friedman non-parametric test for repeated measures. (C and D) Student’s t-test for one sample. Statistical significance: P < 0.05. N = 20 for all time points in each panel. LDL, low-density lipoproteins; D, day.CC BY · PubMed Central
Figure 6 Effect of 4-week intervention with probiotic on lipoprotein functionality. Box plots representing (A) conjugated dienes (CDmax) and (B) the time to achieve the half-maximum oxidation value (time to half-maximum) at baseline and Days 14 and 28. (C) Correlation between conjugated dienes average change and LDL lipoprotein average change represented in bivariate scattergram and Spearman and Pearson coefficients. (D) Table with Pearson and Spearman correlation coefficient between conjugated dienes and LDL lipoprotein levels at baseline and Days 14 and 28. (E) Box plots representing % oxidation of LDL particles. P-value: (A and D) Friedman non-parametric test for repeated measures and Wilcoxon signed-rank test. (B and C) Spearman’s rank and Pearson correlation coefficient tests. Statistical significance: P < 0.05. N = 20 for all time points in each panel. LDL, low-density lipoproteins; D, day; Δ, change.
Figure 6 Effect of 4-week intervention with probiotic on lipoprotein functionality. Box plots representing (A) conjugated dienes (CDmax) and (B) the time to achieve the half-maximum oxidation value (time to half-maximum) at baseline and Days 14 and 28. (C) Correlation between conjugated dienes average change and LDL lipoprotein average change represented in bivariate scattergram and Spearman and Pearson coefficients. (D) Table with Pearson and Spearman correlation coefficient between conjugated dienes and LDL lipoprotein levels at baseline and Days 14 and 28. (E) Box plots representing % oxidation of LDL particles. P-value: (A and D) Friedman non-parametric test for repeated measures and Wilcoxon signed-rank test. (B and C) Spearman’s rank and Pearson correlation coefficient tests. Statistical significance: P < 0.05. N = 20 for all time points in each panel. LDL, low-density lipoproteins; D, day; Δ, change.CC BY · PubMed Central
Figure 7 Analysis of microbiota in faecal samples of study participants at baseline and at Day 28. (A) Box plot representing of alpha diversity (Shannon index). (B) Beta diversity (PCoA based on Bray–Curtis similarity index). (C) Cell line chart of relative abundance (%) of class Desulfovibrio of each individual. P-value: (C) Wilcoxon signed-rank test, significance retained upon adjusting for multiplicity at an FDR of 0.10. P < 0.05. (A and B) N = 20 for all time points. (C) N = 20 at Time 0 and N = 19 at Time 28 (one subject with levels under detection limit). D, day; PCoA, principal coordinate analysis.
Figure 7 Analysis of microbiota in faecal samples of study participants at baseline and at Day 28. (A) Box plot representing of alpha diversity (Shannon index). (B) Beta diversity (PCoA based on Bray–Curtis similarity index). (C) Cell line chart of relative abundance (%) of class Desulfovibrio of each individual. P-value: (C) Wilcoxon signed-rank test, significance retained upon adjusting for multiplicity at an FDR of 0.10. P < 0.05. (A and B) N = 20 for all time points. (C) N = 20 at Time 0 and N = 19 at Time 28 (one subject with levels under detection limit). D, day; PCoA, principal coordinate analysis.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 1 Not valid · 8 Not checked · 120 Own results and interpretations

74 more claims

Create a free account to see all 142 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 52

Create a free account to see these claims.

Citations

Cites

Show all 70 references

Cited by

See all 32

Metadata

Authors
Padro, T., Santisteban, V., Huedo, P., Puntes, M., Aguiló, M., Espadaler-Mazo, J., & Badimon, L.
Affiliations
  • Cardiovascular Program-ICCC, Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU) , Sant Antoni Mª Claret 167, Barcelona 08025 , Spain
  • Universitat Internacional de Catalunya (ES)
  • Medicament Research Center (CIM), Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU) , Barcelona , Spain
  • AB-Biotics (Spain) (ES)
  • R&D Department, AB-Biotics S.A. (Part of Kaneka Corporation) , Barcelona , Spain
Venue
Cardiovascular Research
Published
2024-03-25
Volume
120
Issue
7
Pages
708-722
ISSN
  • 0008-6363 (ISSN-L)
  • 1755-3245
OpenAlex
W4393158089
Cited by
32
References
71
Citations by year
2026: 15 · 2025: 11 · 2024: 6
FWCI
6.85
Type
journal article
Language
en
Open access
Locations
  • Cardiovascular Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
Funders
  • AB-Biotics SA
  • Spanish Ministry of Economy and Competitiveness of Science ‘Agencia Estatal de Investigación (AEI/10.13039/501100011033, PID2019-107160RB-I00)
  • Institute of Health Carlos III (FIS PI19/01687)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
Lactobacillus plantarum, bile salt hydrolase, probiotics, bile acids, cholesterol metabolism, LDL cholesterol, non-HDL cholesterol, FGF19, apolipoprotein B, small dense LDL, LDL oxidation, HDL antioxidant capacity, taurine, Desulfovibrio, gut microbiota, overweight, atherosclerosis, cardiovascular health
MeSH terms
Gastrointestinal Microbiome, Adult, Amidohydrolases, Bile Acids and Salts, Cholesterol, Female, Fibroblast Growth Factors, Humans, Cholesterol, LDL, Male, Middle Aged, Pilot Projects, Time Factors, Biomarkers, Treatment Outcome, Probiotics, Lactiplantibacillus plantarum, Apolipoprotein B-48, Apolipoprotein B-100

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lactiplantibacillus plantarum strains KABP011, KABP012, and KABP013 modulate bile acids and cholesterol metabolism in humans. https://app.cochat.ai/papers/10.1093/cvr/cvae061
The paper
Padro, T., Santisteban, V., Huedo, P., Puntes, M., Aguiló, M., Espadaler-Mazo, J., & Badimon, L. (2024). Lactiplantibacillus plantarum strains KABP011, KABP012, and KABP013 modulate bile acids and cholesterol metabolism in humans. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae061

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.